2018-2025 Recurrent Glioblastoma Multiforme Treatment Report on Global and United States Market, Status and Forecast, by Players, Types and Applications

Publisher Name :
Date: 16-Apr-2018
No. of pages: 121
Inquire Before Buying

Summary

This report studies the Recurrent Glioblastoma Multiforme Treatment market status and outlook of global and United States, from angles of players, regions, product types and end industries; this report analyzes the top players in global and United States market, and splits the Recurrent Glioblastoma Multiforme Treatment market by product type and application/end industries.

The global Recurrent Glioblastoma Multiforme Treatment market is valued at XX million USD in 2017 and is expected to reach XX million USD by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially the United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Recurrent Glioblastoma Multiforme Treatment.

United States plays an important role in global market, with market size of xx million USD in 2017 and will be xx million USD in 2025, with a CAGR of XX.

Geographically, this report is segmented into several key regions, with sales, revenue, market share (%) and growth Rate (%) of Recurrent Glioblastoma Multiforme Treatment in these regions, from 2013 to 2025 (forecast), covering

- United States

- North America

- Europe

- Asia-Pacific

- South America

- Middle East and Africa

The major players in global and United States market, including

- Boehringer Ingelheim GmbH

- Boston Biomedical, Inc.

- Bristol-Myers Squibb Company

- Cantex Pharmaceuticals, Inc.

- Cavion LLC

- Celldex Therapeutics, Inc.

- Coherus BioSciences, Inc.

- Cortice Biosciences, Inc.

- Eisai

- Eli Lilly and Company

- EnGeneIC Ltd

- ERC Belgium SA

- GenSpera, Inc.

- Genzyme Corporation

- GW Pharmaceuticals Plc

- ImmunoCellular Therapeutics, Ltd.

On the basis of product, the market is primarily split into

- AU-105

- Axitinib

- AXL-1717

- AZD-7451

- Others

On the basis on the end users/application, this report covers

- Hospital

- Clinic

- Others

2018-2025 Recurrent Glioblastoma Multiforme Treatment Report on Global and United States Market, Status and Forecast, by Players, Types and Applications

Table of Contents
2018-2025 Recurrent Glioblastoma Multiforme Treatment Report on Global and United States Market, Status and Forecast, by Players, Types and Applications
1 Methodology and Data Source
1.1 Methodology/Research Approach
1.1.1 Research Programs/Design
1.1.2 Market Size Estimation
1.1.3 Market Breakdown and Data Triangulation
1.2 Data Source
1.2.1 Secondary Sources
1.2.2 Primary Sources
1.3 Disclaimer
2 Recurrent Glioblastoma Multiforme Treatment Market Overview
2.1 Recurrent Glioblastoma Multiforme Treatment Product Overview
2.2 Recurrent Glioblastoma Multiforme Treatment Market Segment by Type
2.2.1 AU-105
2.2.2 Axitinib
2.2.3 AXL-1717
2.2.4 AZD-7451
2.2.5 Others
2.3 Global Recurrent Glioblastoma Multiforme Treatment Product Segment by Type
2.3.1 Global Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Growth (%) by Type (2013, 2017 and 2025)
2.3.2 Global Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Market Share (%) by Type (2013-2018)
2.3.3 Global Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) and Market Share (%) by Type (2013-2018)
2.3.4 Global Recurrent Glioblastoma Multiforme Treatment Price (USD/Pcs) by Type (2013-2018)
2.4 United States Recurrent Glioblastoma Multiforme Treatment Product Segment by Type
2.4.1 United States Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Growth by Type (2013, 2017 and 2025)
2.4.2 United States Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Market Share by Type (2013-2018)
2.4.3 United States Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) and Market Share by Type (2013-2018)
2.4.4 United States Recurrent Glioblastoma Multiforme Treatment Price (USD/Pcs) by Type (2013-2018)
3 Recurrent Glioblastoma Multiforme Treatment Application/End Users
3.1 Recurrent Glioblastoma Multiforme Treatment Segment by Application/End Users
3.1.1 Hospital
3.1.2 Clinic
3.1.3 Others
3.2 Global Recurrent Glioblastoma Multiforme Treatment Product Segment by Application
3.2.1 Global Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and CGAR (%) by Application (2013, 2017 and 2025)
3.2.2 Global Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Market Share (%) by Application (2013-2018)
3.3 United States Recurrent Glioblastoma Multiforme Treatment Product Segment by Application
3.3.1 United States Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and CGAR (%) by Application (2013, 2017 and 2025)
3.3.2 United States Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Market Share (%) by Application (2013-2018)
4 Recurrent Glioblastoma Multiforme Treatment Market Status and Outlook by Regions
4.1 Global Market Status and Outlook by Regions
4.1.1 Global Recurrent Glioblastoma Multiforme Treatment Market Size and CAGR by Regions (2013, 2017 and 2025)
4.1.2 North America
4.1.3 Asia-Pacific
4.1.4 Europe
4.1.5 South America
4.1.6 Middle East and Africa
4.1.7 United States
4.2 Global Recurrent Glioblastoma Multiforme Treatment Sales and Revenue by Regions
4.2.1 Global Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Market Share (%) by Regions (2013-2018)
4.2.2 Global Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) and Market Share (%) by Regions (2013-2018)
4.2.3 Global Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
4.2.4 North America Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
4.2.5 Europe Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
4.2.6 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
4.2.7 South America Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
4.2.8 Middle East and Africa Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
4.2.9 United States Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
5 Global Recurrent Glioblastoma Multiforme Treatment Market Competition by Players/Manufacturers
5.1 Global Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Market Share by Players (2013-2018)
5.2 Global Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) and Share by Players (2013-2018)
5.3 Global Recurrent Glioblastoma Multiforme Treatment Average Price (USD/Pcs) by Players (2013-2018)
5.4 Global Top Players Recurrent Glioblastoma Multiforme Treatment Manufacturing Base Distribution, Sales Area, Product Types
5.5 Recurrent Glioblastoma Multiforme Treatment Market Competitive Situation and Trends
5.5.1 Recurrent Glioblastoma Multiforme Treatment Market Concentration Rate
5.5.2 Global Recurrent Glioblastoma Multiforme Treatment Market Share (%) of Top 3 and Top 5 Players
5.5.3 Mergers & Acquisitions, Expansion
6 United States Recurrent Glioblastoma Multiforme Treatment Market Competition by Players/Manufacturers
6.1 United States Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Market Share by Players (2013-2018)
6.2 United States Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) and Share by Players (2013-2018)
6.3 United States Recurrent Glioblastoma Multiforme Treatment Average Price (USD/Pcs) by Players (2013-2018)
6.4 United States Recurrent Glioblastoma Multiforme Treatment Market Share (%) of Top 3 and Top 5 Players
7 Recurrent Glioblastoma Multiforme Treatment Players/Manufacturers Profiles and Sales Data
7.1 Boehringer Ingelheim GmbH
7.1.1 Company Basic Information, Manufacturing Base and Competitors
7.1.2 Recurrent Glioblastoma Multiforme Treatment Product Category, Application and Specification
7.1.2.1 Product A
7.1.2.2 Product B
7.1.3 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
7.1.4 Main Business/Business Overview
7.2 Boston Biomedical, Inc.
7.2.1 Company Basic Information, Manufacturing Base and Competitors
7.2.2 Recurrent Glioblastoma Multiforme Treatment Product Category, Application and Specification
7.2.2.1 Product A
7.2.2.2 Product B
7.2.3 Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
7.2.4 Main Business/Business Overview
7.3 Bristol-Myers Squibb Company
7.3.1 Company Basic Information, Manufacturing Base and Competitors
7.3.2 Recurrent Glioblastoma Multiforme Treatment Product Category, Application and Specification
7.3.2.1 Product A
7.3.2.2 Product B
7.3.3 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
7.3.4 Main Business/Business Overview
7.4 Cantex Pharmaceuticals, Inc.
7.4.1 Company Basic Information, Manufacturing Base and Competitors
7.4.2 Recurrent Glioblastoma Multiforme Treatment Product Category, Application and Specification
7.4.2.1 Product A
7.4.2.2 Product B
7.4.3 Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
7.4.4 Main Business/Business Overview
7.5 Cavion LLC
7.5.1 Company Basic Information, Manufacturing Base and Competitors
7.5.2 Recurrent Glioblastoma Multiforme Treatment Product Category, Application and Specification
7.5.2.1 Product A
7.5.2.2 Product B
7.5.3 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
7.5.4 Main Business/Business Overview
7.6 Celldex Therapeutics, Inc.
7.6.1 Company Basic Information, Manufacturing Base and Competitors
7.6.2 Recurrent Glioblastoma Multiforme Treatment Product Category, Application and Specification
7.6.2.1 Product A
7.6.2.2 Product B
7.6.3 Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
7.6.4 Main Business/Business Overview
7.7 Coherus BioSciences, Inc.
7.7.1 Company Basic Information, Manufacturing Base and Competitors
7.7.2 Recurrent Glioblastoma Multiforme Treatment Product Category, Application and Specification
7.7.2.1 Product A
7.7.2.2 Product B
7.7.3 Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
7.7.4 Main Business/Business Overview
7.8 Cortice Biosciences, Inc.
7.8.1 Company Basic Information, Manufacturing Base and Competitors
7.8.2 Recurrent Glioblastoma Multiforme Treatment Product Category, Application and Specification
7.8.2.1 Product A
7.8.2.2 Product B
7.8.3 Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
7.8.4 Main Business/Business Overview
7.9 Eisai
7.9.1 Company Basic Information, Manufacturing Base and Competitors
7.9.2 Recurrent Glioblastoma Multiforme Treatment Product Category, Application and Specification
7.9.2.1 Product A
7.9.2.2 Product B
7.9.3 Eisai Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
7.9.4 Main Business/Business Overview
7.10 Eli Lilly and Company
7.10.1 Company Basic Information, Manufacturing Base and Competitors
7.10.2 Recurrent Glioblastoma Multiforme Treatment Product Category, Application and Specification
7.10.2.1 Product A
7.10.2.2 Product B
7.10.3 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
7.10.4 Main Business/Business Overview
7.11 EnGeneIC Ltd
7.12 ERC Belgium SA
7.13 GenSpera, Inc.
7.14 Genzyme Corporation
7.15 GW Pharmaceuticals Plc
7.16 ImmunoCellular Therapeutics, Ltd.
8 Recurrent Glioblastoma Multiforme Treatment Manufacturing Cost, Industrial Chain and Downstream Buyers
8.1 Recurrent Glioblastoma Multiforme Treatment Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Price Trend of Key Raw Materials
8.1.3 Key Suppliers of Raw Materials
8.1.4 Market Concentration Rate of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.2.1 Raw Materials
8.2.2 Labor Cost
8.2.3 Manufacturing Expenses
8.3 Recurrent Glioblastoma Multiforme Treatment Industrial Chain Analysis
8.4 Downstream Buyers in United States
9 Marketing Strategy Analysis, Distributors and Market Effect Factors
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Distributors in Untied States
9.3 Market Effect Factors Analysis
9.3.1 Economic/Political Environmental Change
9.3.2 Downstream Demand Change
9.3.3 Technology Progress in Related Industry
9.3.4 Substitutes Threat
10 Global Recurrent Glioblastoma Multiforme Treatment Market Forecast
10.1 Global Recurrent Glioblastoma Multiforme Treatment Sales, Revenue Forecast (2018-2025)
10.1.1 Global Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Growth Rate (%) Forecast (2018-2025)
10.1.2 Global Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) and Growth Rate (%) Forecast (2018-2025)
10.2 United States Recurrent Glioblastoma Multiforme Treatment Market Forecast
10.2.1 United States Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Growth Rate (%) Forecast (2018-2025)
10.2.2 United States Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) and Growth Rate (%) Forecast (2018-2025)
10.3 Global Recurrent Glioblastoma Multiforme Treatment Forecast by Regions
10.3.1 North America Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Revenue (Million USD) Forecast (2018-2025)
10.3.2 Europe Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Revenue (Million USD) Forecast (2018-2025)
10.3.3 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Revenue (Million USD) Forecast (2018-2025)
10.3.4 South America Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Revenue (Million USD) Forecast (2018-2025)
10.3.5 Middle East and Africa Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Revenue (Million USD) Forecast (2018-2025)
10.4 Recurrent Glioblastoma Multiforme Treatment Forecast by Type
10.4.1 Global Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Revenue (Million USD) Forecast by Type (2018-2025)
10.4.2 United States Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Revenue (Million USD) Forecast by Type (2018-2025)
10.5 Recurrent Glioblastoma Multiforme Treatment Forecast by Application
10.5.1 Global Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) Forecast by Application (2018-2025)
10.5.2 United States Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) Forecast by Application (2018-2025)
11 Research Findings and Conclusion
List of Tables and Figures
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
Figure Recurrent Glioblastoma Multiforme Treatment Product Picture
Figure Global Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) Status and Outlook (2013-2025)
Figure United States Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) Status and Outlook (2013-2025)
Figure Product Picture of AU-105
Table Major Players of AU-105
Figure Global AU-105 Sales (K Pcs) and Growth Rate (%)(2013-2018)
Figure Product Picture of Axitinib
Table Major Players of Axitinib
Figure Global Axitinib Sales (K Pcs) and Growth Rate (%)(2013-2018)
Figure Product Picture of AXL-1717
Table Major Players of AXL-1717
Figure Global AXL-1717 Sales (K Pcs) and Growth Rate (%)(2013-2018)
Figure Product Picture of AZD-7451
Table Major Players of AZD-7451
Figure Global AZD-7451 Sales (K Pcs) and Growth Rate (%)(2013-2018)
Figure Product Picture of Others
Table Major Players of Others
Figure Global Others Sales (K Pcs) and Growth Rate (%)(2013-2018)
Table Global Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Growth Rate (%) Comparison by Type (2013, 2017 and 2025)
Table Global Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) by Type (2013-2018)
Table Global Recurrent Glioblastoma Multiforme Treatment Sales Share (%) by Type (2013-2018)
Figure Global Recurrent Glioblastoma Multiforme Treatment Sales Market Share (%) by Type (2013-2018)
Figure Global Recurrent Glioblastoma Multiforme Treatment Sales Market Share (%) by Type in 2017
Table Global Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) by Type (2013-2018)
Table Global Recurrent Glioblastoma Multiforme Treatment Revenue Share (%) by Type (2013-2018)
Figure Global Recurrent Glioblastoma Multiforme Treatment Revenue Share (%) by Type (2013-2018)
Figure 2017 Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share (%) by Type
Table Global Recurrent Glioblastoma Multiforme Treatment Price (USD/Pcs) by Type (2013-2018)
Table United States Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Growth Rate (%) Comparison by Type (2013, 2017 and 2025)
Table United States Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) by Type (2013-2018)
Table United States Recurrent Glioblastoma Multiforme Treatment Sales Share (%) by Type (2013-2018)
Figure United States Recurrent Glioblastoma Multiforme Treatment Sales Market Share (%) by Type (2013-2018)
Figure United States Recurrent Glioblastoma Multiforme Treatment Sales Market Share (%) by Type in 2017
Table United States Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) by Type (2013-2018)
Table United States Recurrent Glioblastoma Multiforme Treatment Revenue Share (%) by Type (2013-2018)
Figure United States Recurrent Glioblastoma Multiforme Treatment Revenue Share (%)by Type (2013-2018)
Figure 2017 United States Recurrent Glioblastoma Multiforme Treatment Revenue Market Share (%) by Type
Table United States Recurrent Glioblastoma Multiforme Treatment Price (USD/Pcs) by Type (2013-2018)
Figure Hospital Examples
Figure Clinic Examples
Figure Others Examples
Table Global Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) Comparison by Application (2013-2025)
Table Global Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) by Application (2013-2018)
Table Global Recurrent Glioblastoma Multiforme Treatment Sales Share (%) by Application (2013-2018)
Figure Global Recurrent Glioblastoma Multiforme Treatment Sales Market Share (%) by Application (2013-2018)
Figure Global Recurrent Glioblastoma Multiforme Treatment Sales Market Share (%) by Application in 2017
Table United States Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) Comparison by Application (2013-2025)
Table United States Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) by Application (2013-2018)
Table United States Recurrent Glioblastoma Multiforme Treatment Sales Share (%) by Application (2013-2018)
Figure United States Recurrent Glioblastoma Multiforme Treatment Sales Market Share (%) by Application (2013-2018)
Figure United States Recurrent Glioblastoma Multiforme Treatment Sales Market Share (%) by Application in 2017
Table Global Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) and CAGR Comparison by Regions (2013-2025)
Figure North America Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) and Growth Rate (%)(2013-2025)
Figure Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) and Growth Rate (%)(2013-2025)
Figure Europe Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) and Growth Rate (%)(2013-2025)
Figure South America Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) and Growth Rate (%)(2013-2025)
Figure Middle East and Africa Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) and Growth Rate (%)(2013-2025)
Figure United States Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) and Growth Rate (%)(2013-2025)
Table Global Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) by Regions (2013-2018)
Table Global Recurrent Glioblastoma Multiforme Treatment Sales Market Share (%) by Regions (2013-2018)
Figure Global Recurrent Glioblastoma Multiforme Treatment Sales Market Share (%) by Regions (2013-2018)
Figure 2017 Global Recurrent Glioblastoma Multiforme Treatment Sales Market Share (%) by Regions
Figure 2017 United States Recurrent Glioblastoma Multiforme Treatment Sales Market Share (%) in Global Market
Table Global Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) by Regions (2013-2018)
Table Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share (%) by Regions (2013-2018)
Figure Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share (%) by Regions (2013-2018)
Figure 2017 Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share (%) by Regions
Figure 2017 United States Recurrent Glioblastoma Multiforme Treatment Revenue Market Share (%) in Global Market
Table Global Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Table North America Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Table Europe Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Table Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Table South America Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Table Middle East and Africa Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Table United States Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Table Global Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) of Key Players (2013-2018)
Table Global Recurrent Glioblastoma Multiforme Treatment Sales Share (%) by Players (2013-2018)
Figure 2017 Global Recurrent Glioblastoma Multiforme Treatment Sales Share (%) by Players
Figure 2018 Global Recurrent Glioblastoma Multiforme Treatment Sales Share (%) by Players
Table Global Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) by Players (2013-2018)
Table Global Recurrent Glioblastoma Multiforme Treatment Revenue Share (%) by Players (2013-2018)
Table 2017 Global Recurrent Glioblastoma Multiforme Treatment Revenue Share (%) by Players
Table 2018 Global Recurrent Glioblastoma Multiforme Treatment Revenue Share (%) by Players
Table Global Market Recurrent Glioblastoma Multiforme Treatment Average Price (USD/Pcs) by Players (2013-2018)
Table Global Recurrent Glioblastoma Multiforme Treatment Top Players Manufacturing Base Distribution and Sales Area
Table Global Recurrent Glioblastoma Multiforme Treatment Top Players Product Category
Figure Global Recurrent Glioblastoma Multiforme Treatment Market Share (%) of Top 3 Players
Figure Global Recurrent Glioblastoma Multiforme Treatment Market Share (%) of Top 5 Players
Table United States Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) by Players (2013-2018)
Table United States Recurrent Glioblastoma Multiforme Treatment Sales Market Share (%) by Players (2013-2018)
Figure 2017 United States Recurrent Glioblastoma Multiforme Treatment Sales Share (%) by Players
Figure 2018 United States Recurrent Glioblastoma Multiforme Treatment Sales Share (%) by Players
Table United States Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) by Players (2013-2018)
Table United States Recurrent Glioblastoma Multiforme Treatment Revenue Market Share (%) by Players (2013-2018)
Table 2017 United States Recurrent Glioblastoma Multiforme Treatment Revenue Share (%) by Players
Table 2018 United States Recurrent Glioblastoma Multiforme Treatment Revenue Share (%) by Players
Table United States Market Recurrent Glioblastoma Multiforme Treatment Average Price (USD/Pcs) by Players (2013-2018)
Figure United States Recurrent Glioblastoma Multiforme Treatment Market Share (%) of Top 3 Players
Figure United States Recurrent Glioblastoma Multiforme Treatment Market Share (%) of Top 5 Players
Table Boehringer Ingelheim GmbH Basic Information List
Table Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Figure Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Sales Growth Rate (2013-2018)
Figure Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Sales Global Market Share (%)(2013-2018)
Figure Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Revenue Global Market Share (%)(2013-2018)
Table Boston Biomedical, Inc. Basic Information List
Table Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Figure Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Sales Growth Rate (2013-2018)
Figure Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Sales Global Market Share (%)(2013-2018)
Figure Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue Global Market Share (%)(2013-2018)
Table Bristol-Myers Squibb Company Basic Information List
Table Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Figure Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Sales Growth Rate (2013-2018)
Figure Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Sales Global Market Share (%)(2013-2018)
Figure Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Revenue Global Market Share (%)(2013-2018)
Table Cantex Pharmaceuticals, Inc. Basic Information List
Table Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Figure Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Sales Growth Rate (2013-2018)
Figure Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Sales Global Market Share (%)(2013-2018)
Figure Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue Global Market Share (%)(2013-2018)
Table Cavion LLC Basic Information List
Table Cavion LLC Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Figure Cavion LLC Recurrent Glioblastoma Multiforme Treatment Sales Growth Rate (2013-2018)
Figure Cavion LLC Recurrent Glioblastoma Multiforme Treatment Sales Global Market Share (%)(2013-2018)
Figure Cavion LLC Recurrent Glioblastoma Multiforme Treatment Revenue Global Market Share (%)(2013-2018)
Table Celldex Therapeutics, Inc. Basic Information List
Table Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Figure Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Sales Growth Rate (2013-2018)
Figure Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Sales Global Market Share (%)(2013-2018)
Figure Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue Global Market Share (%)(2013-2018)
Table Coherus BioSciences, Inc. Basic Information List
Table Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Figure Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Sales Growth Rate (2013-2018)
Figure Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Sales Global Market Share (%)(2013-2018)
Figure Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue Global Market Share (%)(2013-2018)
Table Cortice Biosciences, Inc. Basic Information List
Table Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Figure Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Sales Growth Rate (2013-2018)
Figure Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Sales Global Market Share (%)(2013-2018)
Figure Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue Global Market Share (%)(2013-2018)
Table Eisai Basic Information List
Table Eisai Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Figure Eisai Recurrent Glioblastoma Multiforme Treatment Sales Growth Rate (2013-2018)
Figure Eisai Recurrent Glioblastoma Multiforme Treatment Sales Global Market Share (%)(2013-2018)
Figure Eisai Recurrent Glioblastoma Multiforme Treatment Revenue Global Market Share (%)(2013-2018)
Table Eli Lilly and Company Basic Information List
Table Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Figure Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Sales Growth Rate (2013-2018)
Figure Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Sales Global Market Share (%)(2013-2018)
Figure Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Revenue Global Market Share (%)(2013-2018)
Table EnGeneIC Ltd Basic Information List
Table ERC Belgium SA Basic Information List
Table GenSpera, Inc. Basic Information List
Table Genzyme Corporation Basic Information List
Table GW Pharmaceuticals Plc Basic Information List
Table ImmunoCellular Therapeutics, Ltd. Basic Information List
Table Sales Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Recurrent Glioblastoma Multiforme Treatment
Figure Recurrent Glioblastoma Multiforme Treatment Industrial Chain Analysis
Table Major Buyers of Recurrent Glioblastoma Multiforme Treatment
Table Distributors/Traders List
Figure Global Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Growth Rate (%) Forecast (2018-2025)
Figure Global Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) and Growth Rate (%) Forecast (2018-2025)
Figure United States Recurrent Glioblastoma Multiforme TreatmentRecurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Growth Rate (%) Forecast (2018-2025)
Figure United States Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) and Growth Rate (%) Forecast (2018-2025)
Table Global Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) Forecast by Regions (2018-2025)
Figure Global Recurrent Glioblastoma Multiforme Treatment Sales Market Share (%) Forecast by Regions (2018-2025)
Figure North America Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Growth Rate (%) Forecast (2018-2025)
Figure North America Recurrent Glioblastoma Multiforme Treatment Revenue and Growth Rate (%) Forecast (2018-2025)
Figure Europe Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Growth Rate (%) Forecast (2018-2025)
Figure Europe Recurrent Glioblastoma Multiforme Treatment Revenue and Growth Rate (%) Forecast (2018-2025)
Figure Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Growth Rate (%) Forecast (2018-2025)
Figure Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Revenue and Growth Rate (%) Forecast (2018-2025)
Figure South America Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Growth Rate (%) Forecast (2018-2025)
Figure South America Recurrent Glioblastoma Multiforme Treatment Revenue and Growth Rate (%) Forecast (2018-2025)
Figure Middle East and Africa Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) and Growth Rate (%) Forecast (2018-2025)
Figure Middle East and Africa Recurrent Glioblastoma Multiforme Treatment Revenue and Growth Rate (%) Forecast (2018-2025)
Table Global Recurrent Glioblastoma Multiforme Treatment Sales (Million USD) Forecast by Type (2018-2025)
Figure Global Recurrent Glioblastoma Multiforme Treatment Sales Market Share (%) Forecast by Type (2018-2025)
Table Global Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) Forecast by Type (2018-2025)
Figure Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share (%) Forecast by Type (2018-2025)
Table United States Recurrent Glioblastoma Multiforme Treatment Sales (Million USD) Forecast by Type (2018-2025)
Figure United States Recurrent Glioblastoma Multiforme Treatment Sales Market Share (%) Forecast by Type (2018-2025)
Table United States Recurrent Glioblastoma Multiforme Treatment Revenue (Million USD) Forecast by Type (2018-2025)
Figure United States Recurrent Glioblastoma Multiforme Treatment Revenue Market Share (%) Forecast by Type (2018-2025)
Table Global Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) Forecast by Application (2018-2025)
Figure Global Recurrent Glioblastoma Multiforme Treatment Sales Forecast by Application (2018-2025)
Table United States Recurrent Glioblastoma Multiforme Treatment Sales (K Pcs) Forecast by Application (2018-2025)
Figure United States Recurrent Glioblastoma Multiforme Treatment Sales Forecast by Ap
  • Global and United States Propolis Market Research by Company, Type & Application 2013-2025
    Published: 15-Jul-2018        Price: US 2000 Onwards        Pages: 152
    Summary Market Segment as follows: By Type - Supercritical Extraction CO2 (SFE) - Ethanol Extracted Propolis (EEP) - Glycol Extracted Propolis (GEP) - Others By Application - Food Industry - Cosmetic Industry - Pharmaceutical Industry - Others By Company - Apis Flora - Wax Green - Comvita - Polenectar - King's Gel - MN Propolis - Evergreen - Ponlee - ......
  • Global and United States Saffron Extract Market Research by Company, Type & Application 2013-2025
    Published: 15-Jul-2018        Price: US 2000 Onwards        Pages: 123
    Summary Market Segment as follows: By Type - Thread - Powder - Liquid By Application - Food - Medical & Pharmaceuticals - Cosmetics - Others By Company - Safrante Global Company S.L.U. - Evolva - Rowhani Saffron Co - Sara Nuts - Tarvand Saffron Co - Hijos de Eustaquio Abad & Co. S.L. - USMS Saffron Co.Inc - Royal Saffron Company - Saharkhiz International Gro......
  • Global and United States Recombinant Protein Drugs Market Research by Company, Type & Application 2013-2025
    Published: 14-Jul-2018        Price: US 2000 Onwards        Pages: 130
    Summary Market Segment as follows: By Type - Recombinant DNA - Recombinant RNA By Application - Pharmaceutical Industry - Others By Company - Novo Nordisk - Amgen - Sanofi - Eli Lilly - Merck Serono - Ortho Biotech - Roche - Kyowa Hakko Kirin - Pharmingen - Abcam - GenSci - SL PHARM - Dongbao Pharm - Ankebio - NCPC - Heng Rui......
  • Global and United States Nano Pharmaceutical Market Research by Company, Type & Application 2013-2025
    Published: 13-Jul-2018        Price: US 2000 Onwards        Pages: 131
    Summary Market Segment as follows: By Type - Natural Material Carrier - High Polymer Material Carrier By Application - Medical - Scientific Research - Others By Company - Sanofi - Merck - Pfizer - Cerulean Pharma - Selecta Biosciences - Nanobiotix - Magforce - Celgene - Celsion Corporation - Novsrtisnamiyaow - GSK - Eli Lilly - Astrazeneca......
  • Global and United States P2X Purinoceptor 3 Market Research by Company, Type & Application 2013-2025
    Published: 13-Jul-2018        Price: US 2000 Onwards        Pages: 121
    Summary Market Segment as follows: By Type - OSX-300 - ASN-009 - BLU-5937 - Others By Application - Abdominal Pain - Endometriosis - Idiopathic Pulmonary Fibrosis - Insomnia - Interstitial - Others By Company - Asana BioSciences LLC - Bayer AG - BELLUS Health Inc - Integral Molecular Inc - Merck & Co Inc - Neurim Pharmaceuticals Ltd - Pfizer Inc......
  • Global Streptokinase Market Research Report 2018
    Published: 13-Jul-2018        Price: US 2900 Onwards        Pages: 96
    This report studies the global Streptokinase market status and forecast, categorizes the global Streptokinase market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. The global Streptokinase market is valued at million US$ in 2017 and will reach million US$ by the end of 2025, growing at a CAGR of during 2018-2025. The major ......
  • Investigation Report on Chinese Epoetin Alfa Market, 2018-2022
    Published: 13-Jul-2018        Price: US 2200 Onwards        Pages: 30
    Description Epoetin Alfa refers to erythropoietin (EPO). EPO in the human body is a hormone-like substance secreted by the kidneys and liver to promote erythropoiesis. The indications for EPO approved in China are renal anemia, chemotherapy-induced anemia, and perioperative erythrocyte mobilization. In Jun. 1989, FDA-approved Epoetin Alfa was launched in the U.S. in the trade name of "Epogen". It is sold in over 40 countries nowadays. The report in ......
  • Investigation Report on Chinese Pregabalin Market, 2018-2022
    Published: 13-Jul-2018        Price: US 2200 Onwards        Pages: 30
    Description Pregabalin is a new-generation drug for neuralgia treatment. In Jul. 2004, it was approved by the European Union to treat some epileptic seizures in adults. In Dec. 2004, it was approved by the U.S. Food and Drug Administration (FDA) to treat diabetic peripheral neuralgia and postherpetic neuralgia. In 2006, generalized anxiety disorder and social anxiety disorder became new indications of Pregabalin. In 2007, Pregabalin was approved by the FDA as the first drug to tre......
  • 2018-2023 Global Intravesical Bacillus Calmette Consumption Market Report
    Published: 12-Jul-2018        Price: US 4660 Onwards        Pages: 135
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Intravesical Bacillus Calmette market for 2018-2023. Intravesical Bacillus Calmette is used to treat a certain type of bladder cancer. Bladder cancer is the growth of abnormal or cancerous cells on the inner lining of the bladder wall. BCG helps prevent the cancer from coming back in the bladder lining, and also reduces the risk of it becoming invasive.......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs